Kornimate/medical-research-clean huggingface dataset:
acute tendon and nerve responses to exercise

Conditions: Spinal Cord Injury

Summary: the purpose of this study is to use ultrasound to analyze the effects of a bout of circuit training on the upper extremity of persons with spinal cord injury and able-bodied controls.

background: manual wheelchair propulsion is a primary source of mobility for many individuals with spinal cord injury (sci). propelling a manual wheelchair over an extended period often leads to arm pain and, subsequently, to secondary disability. over 50% of manual wheelchair users with sci experience arm pain that limits their activities of daily living. the prevalence of shoulder pain and carpal tunnel syndrome among manual wheelchair users is between 31% and 73%, and 49% and 73% respectively. a circuit training protocol has been developed to strengthen and protect the muscles of people with sci, and has been shown to improve muscle strength and endurance, and reduce hdlcholesterol levels. purpose: the purpose of this study is to use ultrasound to analyze the effects of a bout of circuit training on the upper extremity of persons with sci and able-bodied controls. hypotheses: all subjects will show an increase in nerve cross-sectional area after participation in the circuit training protocol. nerves and tendons will become less echogenic after participation in the circuit training protocol. these changes will be more pronounced in persons with sci. methods: data collected will include history of pain, a physical exam, and ultrasound images of the nondominant upper extremity before and after a bout of circuit training, which includes exercises lifting weights and using an arm cycle. before circuit training, ultrasound images will be collected once. after the circuit training, ultrasound images will be collected every 10 minutes over an hour. these images and will be used to measure the health and properties (such as size) of nerves, muscles, and tendons in the arm. changes in these properties after a bout of circuit training will be related to history and physical exam information.

Eligibility criteria:
inclusion criteria: spinal cord injury cohort: * any cause or severity of spinal cord injury * at least 1 year post-injury able-bodied control cohort: * self-reported good health exclusion criteria: * history of non-dominant traumatic upper extremity injury to both wrist and shoulder * history of cardiopulmonary or other disease for which intense activity carries any risk of harm * a progressive or degenerative disability

Keywords: healthy control
surveillance for antiviral resistant variants in chronic hepatitis c patients

Conditions: Chronic Hepatitis C Infection

Summary: this is a multi-centre prospective longitudinal cohort study with the aim of collecting and storing clinical data, patient blood, dna and pbmcs to examine outcomes related to drug resistance, drug monitoring and host genetics in the era of directly acting antiviral drugs for hepatitis c therapy.

1. to analyse for resistance-associated hcv variants in daa-naïve hcv patients using population and ultra-deep pyrosequencing (udps). resistance associated variants will be analysed by qualitative and quantitative methods both pre-treatment and on-treatment. 2. to determine whether in the absence of drug pressure there is variation in the prevalence of naturally occurring resistance associated variants. 3. to correlate the presence and frequency of baseline resistance-associated variants with the response to therapy with daa-based triple therapy regimens for hcv. 4. to identify predictors of emergent daa resistance and treatment failure during therapy with daa-based combination strategies, including virological, clinical and immunological factors. 5. to characterize the natural history of hcv resistance associated variants that are selected during antiviral therapy after the withdrawal of treatment. 6. to establish a cohort of daa-treatment failure patients suitable for re-treatment studies. 7. to establish a tissue repository of serum and pbmcs from well-characterized patients treated with daa-based triple therapy to allow future examination of the role of other variables that may potentially impact on the outcomes of daa based therapy and development of ravs.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c infection * commencing or expected to commence daa-based hcv treatment within the next year * ifn treatment-naïve or ifn treatment-experienced * provision of written, informed consent exclusion criteria: * in the opinion of the investigator that the patient is not able to provide informed consent * inability or unwillingness to comply with study collection requirements

Keywords: hepatitis c, chronic
intra-operative ventilatory management & post-operative pulmonary complications

Conditions: Intra-Operative Ventilatory Management; Post-Operative Complications

Summary: background: the list of studies with inconsistent data regarding the effect of intra-operative ventilatory management on post-operative lung injury is large. the literature is lacking data on the least injurious way of ventilating surgical patients intra-operatively. this study is necessary to support future guidelines on the practice of intra-operative mechanical ventilation. specific aim: the aims of this study is first to describe intra-operative ventilatory practices at the american university of beirut medical center (aubmc), (with particular focus on the mode of ventilation, tidal volume per body weight and peep settings) and second, to identify the post-operative complications that could be associated with particular settings. methodology: this is a prospective observational study that will be conducted in the operating room at aubmc, on patients being admitted for surgeries under general anesthesia. during the patient's stay in the hospital, targeted process (patient characteristics, surgical procedure, mechanical ventilation management, anesthesiologist characteristics) and outcomes parameters (postoperative pulmonary complications) will be collected for analysis. patients will be monitored and followed up with intraoperatively and postoperatively. analysis: different parameters and outcomes will be collected and by subgrouping the patients per their medical history statistical significance will be tested to reach a correlative analysis to the outcomes documented. statistical comparison will be made using the anova, student's t-test, and chi-squared test. level of statistical significance will be considered at p\<0.05. mean age, weight, height and bmi of participants in the different groups will be calculated. anova test will be performed to test statistical significance to compare the different means between different subgroups. a two sided p value of less than 0.05 was considered to be significant significance: the literature is lacking data on the least injurious way of ventilating surgical patients intra-operatively. this study is necessary to support future guidelines on the practice of intra-operative mechanical ventilation


Eligibility criteria:
inclusion criteria: 1. surgeries undergone under general anesthesia 2. patients above 18 years old 3. patient able to give consent 4. american society of anesthesiologists (asa) = 1 to 4 exclusion criteria: 1. patients unable to give consent 2. patients below 18 years old. 3. surgeries done under spinal anesthesia or local block or under sedation. 4. patients admitted to intensive care unit post-operative due to surgical complications.
effects of music and dance on cognition, frailty, and burden in elderly caregivers living in rural communities

Conditions: Cognitive Decline; Memory Loss; Frail Elderly Syndrome; Burden, Dependency

Summary: this research aims to analyze the effects of senior dance on the cognition, frailty, and burden in elderly caregivers of rural communities. this is a randomized clinical trial to be conducted with a sample of 58 elderly caregivers residing in rural communities. data collection will be performed in the homes of the elderly and/or in the dependencies of the family health units (usfs - primary health care systems). they will answer socio-demographic characterization instrument, ace-r battery, and electroencephalography for cognitive evaluation, five fragility criteria proposed by fried et al and zarit burden inventory. the dance protocol will be applied to the experimental group (n=29) in the usfs and the control group (n=29) will receive health care, including guidance on health care and practices. the protocols include 24 interventions, 60 minutes each, weekly, during 6 months. analysis of effects comparisons will be conducted between groups and be comparing baseline with final measurements. dance intervention is expected to exert important positive effects on all study variables (cognitive performance, fragility assessment, and caregiver burden), compared to the group. the intervention of the control group is expected to exert positive effects on some variables of the study (mainly, caregiver burden).

sample variables above described of 58 participants will be measured. the participants will be randomized to the dance group (experimental) and to the health care guidance group (control). the group will be paired by age, sex, and schooling. this study focused on prevention of cognitive performance decline, frailty and burden.

Eligibility criteria:
inclusion criteria: 1. - caregivers of elderly registered in units of family health system in rural communities of são carlos, brazil. 2. - over 60 years old. 3. - living rural area. exclusion criteria: 1 - sufficient sensory or language difficulties that impede the participation of the intervention and the measurement of the variables

Keywords: prevention cognition aged care caregivers frail elderly dancing therapy rural population
pioglitazone versus metformin in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: type 2 diabetes is an epidemic. its long-term consequences translate into enormous human suffering and economic costs; however, much of the morbidity associated with long-term microvascular and neuropathic complications can be substantially reduced by interventions that achieve glucose levels close to the nondiabetic range. however, none of the recent intervention studies has demonstrated a benefit of intensive glycemic control on their primary cvd outcomes. the investigators report the findings of a long-term randomized and comparator-controlled clinical trial conducted in patients with newly-diagnosed type 2 diabetes. the investigators compared the effect of pioglitazone with that of metformin on circulating endothelial cell-derived submicroscopic membranous vesicles, termed microparticles: because of their putative role in inflammatory processes and their ability to directly affect endothelial functions, they are gaining increasing popularity as a surrogate marker of cardiovascular outlook. metformin was chosen as a comparator because the american diabetes association recommendations suggest to start therapy in newly-diagnosed type 2 diabetic subjects combining a drug (metformin) with lifestyle changes. moreover, the mechanism of action of pioglitazone is distinct from that of metformin.


Eligibility criteria:
inclusion criteria: * men and women aged 30-75 years, with newly-diagnosed type 2 diabetes (according to the ada criteria) and never treated with antihyperglycemic drugs, were selected for the study. inclusion criteria also included a body mass index (bmi) \>25 kg/m2, and hba1c level \<10%. exclusion criteria: * pregnancy or breast-feeding * any investigational drug within the previous 3 months * use of agents affecting glycemic control (systemic glucocorticoids, and weight-loss drugs) * presence of any clinically relevant somatic or mental diseases that anticipated poor adherence to diet regimens * to minimize the likelihood of including subjects with late-onset type 1 diabetes, candidates with a positive test for anti-gad antibody or with fasting plasma c-peptide less than 0.76 ng/l (\<0.25 pmol/l) were excluded * also excluded were patients with abnormal laboratory tests, including liver enzymes (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase) greater than 3 times the upper limit of normal, and serum creatinine greater than 123.8 μmol/l (1.4 mg/dl).
control study of nautilus brainpulse for the detection of concussion

Conditions: Brain Concussion

Summary: to use the nautilus brainpulse to compare and contrast the signal patterns from this cohort's signal patterns with those of concussed high school athletes.

this study is a non-blinded study in high school athletes who will be presumed to no be suffering from a concussion. healthy controls will be recruited from high school sports that are not associated with physical contact, which could generate concussions. the primary objective of this study is to improve jan medical's signal analysis. jan medical will perform analysis.

Eligibility criteria:
inclusion criteria: * male and female between 14 and 19 years of age * participating in non-contact sport at the freshman, jv, and varsity level in a bay area high school * able to provide signed informed consent or have a legally authorized representative willing to provide informed consent on the subject's behalf exclusion criteria: * history, if any, of concussion or stroke * history, if any, of alcohol or drug abuse * history, if any, of mental disorder or cerebrovascular disorder * pregnant women * failure to comply with recording schedule * not suitable for participation in the study in the opinion of the pi * have suffered a concussion during the study * plays a contact sport (ex- football, lacrosse, basketball, soccer, ice hockey, cross-country) * related to a jan medical employee
multicenter register for children and young adults with intracranial localized medulloblastoma, cns-pnet or ependymoma

Conditions: Medulloblastoma, Childhood; Cerebral Primitive Neuroectodermal Tumor; Ependymoma

Summary: the register is based on the study hit 2000 that recruited patients until 31.12.2011. all german patients with intracranial medulloblastoma, cns-pnet, ependymoma can be included in the register. object of the register is to maintain the quality of diagnostic standard by using of central review (neuroradiology, pathology, and cranio spinal fluid (csf) cytology). furthermore, the register should enable to continue the collection of epidemiologic data and biological material (tumor material, csf, and blood) for associated studies.

the register is based on the study hit 2000 that recruited patients until 31.12.2011. all german patients with intracranial medulloblastoma, cns-pnet, ependymoma can be included in the register. object of the register is to maintain the quality of diagnostic standard by using of central review (neuroradiology, pathology, and cranio spinal fluid (csf) cytology). furthermore, the register should enable to continue the collection of epidemiologic data and biological material (tumor material, csf, and blood) for associated studies. the register gives recommendations for the therapy of the patients, but these are not mandatory.

Eligibility criteria:
inclusion criteria: * age at diagnosis 0-21 years * histologically proven medulloblastoma, cns-pnet (incl. pineoblastoma, ependymoblastoma, cns-neuroblastoma), or ependymoma (who ii/ iii) exclusion criteria: * none
the study to evaluate the performance and safety of the novasight hybrid system using objective performance criteria

Conditions: Coronary Artery Disease

Summary: this prospective, multicenter, single-arm study aims to evaluate the safety, operability and practicability of the novel hybrid intravascular imaging system/catheter during the percutaneous transluminal coronary intervention.


Eligibility criteria:
inclusion criteria: 1. subject must be at least 18 years of age and less than 85 years of age. 2. subject must be informed and sign a written consent 3. subject must have evidence of myocardial ischemia, unstable angina or acute myocardial infarction suitable for pci. exclusion criteria: 1. women who are pregnant or cannot eliminate the possibility to be pregnant. 2. estimated creatinine clearance \<30 ml/min/1.73 m2 using cockcroft equation. 3. lvef(left ventricular ejection fraction) \< 35% by the most recent imaging test within 7 days prior to procedure. 4. unstable ventricular arrhythmias. 5. high bleeding risk, active peptic ulcers or cerebrovascular accident or transient ischemic attack within the past 6 months. 6. known contraindication to anticoagulants and antiplatelets therapy. 7. known hypersensitivity to aspirin, clopidogrel, heparin, iodinated contrast, ticagrelor, bivalirudin, metal materials in stent. 8. any intervention for not target vessel within 48 hours after the study procedure. 9. any conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation. angiographic exclusion criteria: 1. the reference diameter of target vessel is less than 2.5 mm. 2. the target lesion involves myocardial bridge. 3. the target lesion is in the left main coronary artery or the damage is observed in the ostium. 4. severe calcification in the target vessel. 5. severe tortuosity in the target vessel. 6. multiple contiguous stent implantation in the target vessel. 7. subject has coronary artery spasm. 8. in-stent restenosis. 9. any study lesion characteristic that, in the investigator's opinion, is not available for intravascular imaging.

Keywords: intravascular imaging intravascular ultrasound optical coherence tomography
scripps tumorgraft study

Conditions: Solid Tumor Malignancy or Hematologic Malignancy

Summary: study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.


Eligibility criteria:
inclusion criteria: * age 21 or over * diagnosis of a solid tumor malignancy, either resectable or metastatic or a hematologic malignancy * cognitively and emotionally able to give informed consent exclusion criteria: * under age 21 * not cognitively or emotionally able to give informed consent
ivabradine in patients with congestive heart failure

Conditions: Congestive Heart Failure

Summary: the aim of this study is to assess the efficacy of ivabradine therapy in patients with congestive heart failure using the cardiac biomarkers nt-pro bnp and neopterin.

* approval will be obtained from research ethics committee of faculty of pharmacy, damanhour university * all participants have agreed to take part in this clinical study and provide informed consent * a 3 months, prospective interventional study. * sixty ambulatory, clinically stable symptomatic patients with systolic chronic hf (≥ 4 weeks), on optimized standard medical therapy were consecutively included and randomly allocated to the ivabradine group (n=30) and non-ivabradine group (n=30). * the baseline evaluation comprised physical examination, nyha class, 12-lead electrocardi¬ography (ecg), echocardiography, blood sampling for laboratory measurements, including nt-pro bnp and neopterin. * patients in the ivabradine group were administered ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to hr at rest and tolerability. * patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study. * peripheral venous blood samples were drawn between 8 and 9 am after a 30-min rest in the supine position. serum samples were frozen at -80°c until assay. * levels of nt-pro bnp and neopterin were detected using elisa kits as prescribed by manufacturer. * statistical tests appropriate to the study will be conducted to evaluate significance of results * results, conclusion, discussion and recommendations will be given

Eligibility criteria:
inclusion criteria: * patients with chronic hf, on optimized medical therapy according to european society of cardiol¬ogy guidelines, with lv ejection fraction (lvef) \ 70/min were eligible for inclusion in the study. exclusion criteria: * acute decompen¬sation (acute coronary syndromes and acute hf); * hemodynamically significant valve disease; * cer¬ebrovascular events during the previous 6 months; * dysfunctional prosthetic heart valve; * obstructive or non-obstructive cardiomyopathy; uncorrected congenital heart disease; active myocarditis; * a his¬tory of resuscitation from sudden death; an absence of stable sinus rhythm, severe arrhythmias; hr \< 60 bpm; sick sinus syndrome; second-degree and third-degree atrioventricular block; * severe obesity (body mass index \> 36 kg/m²); * established or sus¬pected pulmonary diseases (vital capacity \< 80% or forced expiratory volume in 1 s \< 80% of age spe¬cific and sex-specific reference values); * hemoglobin ≤ 11 g/dl; * treatment with non-dihydropyridine calcium-channel blockers, class i antiarrhythmic agents, strong inhibitors of cytochrome p450-3a4, or qt interval-prolonging medications; * acute and chronic kidney failure; * pregnancy; hypo- and hy¬perthyroidism or acute infections.
dijon stroke cohort

Conditions: CVA, Dijon Registry

Summary: the dijon stroke registry, accredited by the registry evaluation committee, inserm and public health france, has been studying the epidemiology of cerebrovascular accidents (cerebral infarction, intracerebral haemorrhages, meningeal haemorrhages) and transient ischaemic attacks (tias) within the city of dijon since 1985. as a result of the development of therapies for acute disease, the prognosis of patients has improved over time. thus, the number of stroke survivors has increased by 90% between the 1980s and today. this raises new issues: risk of vascular recurrence, drug iatrogeny, and functional impact of stroke for motor, cognitive or thymic function. in the absence of available data in france, the investigators wish to set up an extended cohort follow-up of patients in order to study their long-term prognosis and to study the impact of future therapies on the evolutionary course of the disease.


Eligibility criteria:
inclusion criteria: * patients included in the dijon stroke registry and not opposed to participating exclusion criteria: * minor patients; opposition to participation